8-K: Immunovant Announces Positive Phase 2a Results for Batoclimab in Graves' Disease, Plans Pivotal Trial for IMVT-1402

Immunovant reported positive Phase 2a trial results for batoclimab in Graves' Disease, showing a 76% response rate and 56% ATD-free response rate with high-dose treatment, and announced the initiation of a pivotal trial for IMVT-1402 by the end of the year.

Summary

• Immunovant has released positive results from its Phase 2a trial of batoclimab in patients with Graves' Disease who were uncontrolled on antithyroid drugs (ATDs).
• The trial showed that a high dose of batoclimab (680mg weekly) resulted in a 76% response rate, defined as T3 and T4 levels falling below the upper limit of normal without increasing the ATD dose, after 12 weeks.
• Additionally, 56% of patients achieved an ATD-free response, meaning their T3 and T4 levels normalized and they were able to completely stop taking ATDs after 12 weeks of high-dose batoclimab.
• A lower dose of batoclimab (340mg weekly) in the subsequent 12 weeks resulted in a 68% response rate and a 36% ATD-free response rate, indicating a correlation between IgG reduction and clinical outcomes.
• Patients who achieved at least a 70% IgG reduction had a nearly threefold higher ATD-free response rate (60% vs. 23%).
• The company has received FDA clearance for its Investigational New Drug (IND) application for IMVT-1402 and plans to initiate a pivotal trial by December 31, 2024.
• Market research indicates that 25-30% of Graves' Disease patients are uncontrolled on ATDs, representing a significant commercial opportunity.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results and a clear path forward with a pivotal trial, indicating strong potential for the company's drug candidates. The sentiment is very positive, but tempered by the inherent risks of drug development and the need for additional capital.

Positives

• The 76% response rate and 56% ATD-free response rate with high-dose batoclimab are very promising.
• The correlation between IgG reduction and clinical outcomes suggests a clear mechanism of action.
• The FDA clearance of the IND for IMVT-1402 allows for a swift transition to a pivotal trial.
• The large percentage of patients uncontrolled on ATDs highlights a significant market opportunity.
• Batoclimab was well-tolerated with no new safety signals identified.

Negatives

• The lower dose of batoclimab resulted in a reduced response rate and ATD-free response rate compared to the higher dose.
• Two patients discontinued the trial, one due to pre-existing gallstones and another due to substance abuse unrelated to treatment.

Risks

• The success of the pivotal trial for IMVT-1402 is not guaranteed.
• The company will require additional capital to fund its operations and advance IMVT-1402 and batoclimab through clinical development.
• There are risks associated with clinical trials, regulatory approvals, and commercialization of the product.
• Macroeconomic and geopolitical factors could impact the company's business operations and supply chain.

Future Outlook

Immunovant expects to initiate a pivotal trial of IMVT-1402 in Graves' Disease by the end of 2024 and believes IMVT-1402 has the potential to be a best-in-class and first-in-class treatment option.

Management Comments

• Pete Salzmann, M.D., chief executive officer of Immunovant, stated that the results validate a large unmet medical need and demonstrate strong response rates.
• Management believes the correlation between clinical response and IgG lowering is impressive.

Industry Context

The announcement highlights the significant unmet need in Graves' Disease treatment, where current options are limited and often ineffective for a substantial portion of patients. The positive results for batoclimab and the planned pivotal trial for IMVT-1402 position Immunovant as a potential leader in this space.

Comparison to Industry Standards

• The 76% response rate and 56% ATD-free response rate with high-dose batoclimab are significantly higher than the typical outcomes seen with standard-of-care treatments like ATDs, which often fail to achieve remission in a substantial portion of patients.
• Current treatments for Graves' Disease, such as anti-thyroid drugs, radioactive iodine, and thyroidectomy, have limitations including side effects, relapse rates, and the need for lifelong hormone replacement therapy.
• The document references Tepezza, a successful treatment for Thyroid Eye Disease (TED), as an example of a targeted therapy that rapidly gained market share, suggesting a similar potential for IMVT-1402 in Graves' Disease.
• The document highlights that 25-30% of Graves' Disease patients are uncontrolled on ATDs, which is a significant portion of the patient population that is not adequately addressed by current treatments.

Stakeholder Impact

• Shareholders are likely to react positively to the promising clinical trial results and the initiation of a pivotal trial.
• Patients with Graves' Disease may benefit from a new treatment option that addresses the underlying disease pathology.
• Employees of Immunovant may be motivated by the positive progress of the company's drug candidates.

Next Steps

• Immunovant will initiate a pivotal trial of IMVT-1402 in Graves' Disease by the end of 2024.
• The company will continue to develop and advance IMVT-1402 and batoclimab through clinical development.

Key Dates

Keywords

Graves' Disease, Immunovant, batoclimab, IMVT-1402, autoimmune disease, anti-thyroid drugs, IgG reduction, clinical trial, FDA, pivotal trial